Study explores MSH2 and MSH6 as markers in canine lung cancer
Bottom line
A new paper in Animals examines whether two mismatch repair proteins, MSH2 and MSH6, are expressed in canine primary pulmonary carcinoma, a relatively uncommon but clinically important lung cancer in dogs. In a 17-case series, the authors evaluated tumors with immunohistochemistry for MCK, TTF-1, MSH2, and MSH6, and correlated staining patterns with clinicopathologic features. The dogs had a median age of 10.6 years, 16 tumors were adenocarcinomas and one was an adenosquamous carcinoma, and papillary architecture was the predominant pattern. The study positions MSH2 and MSH6 as candidate biomarkers in canine lung tumors, an area that has been much better studied in human oncology than in veterinary medicine. (pubmed.ncbi.nlm.nih.gov)
Why it matters: For veterinary professionals, the study adds to a growing push toward more molecularly informed pathology in canine oncology. Mismatch repair biology already matters in human cancer because deficient tumors can carry diagnostic, prognostic, and therapeutic implications, including relevance to immunotherapy. In dogs, that framework is still early, but recent comparative oncology work has underscored the need for validated canine mismatch repair assays, while broader veterinary oncology guidance has stressed careful evaluation before adopting new cancer diagnostics into practice. For clinicians and pathologists, this paper is best read as a signal-generating study that may help refine tumor characterization and future biomarker development, rather than as something ready to change case management today. (pubmed.ncbi.nlm.nih.gov)
What to watch: Watch for larger, outcome-linked studies that test whether MSH2/MSH6 expression in canine lung tumors tracks with prognosis, treatment response, or future precision oncology workflows. (pubmed.ncbi.nlm.nih.gov)
Key facts
- Study type
- Immunohistochemistry study
- Journal
- Animals
- Tumor type
- Canine primary pulmonary carcinoma
- Sample size
- 17 cases
- Markers evaluated
- MCK, TTF-1, MSH2, and MSH6
- Median age
- 10.6 years
- Histology
- 16 adenocarcinomas, one adenosquamous carcinoma
- Predominant pattern
- Papillary architecture
A newly published Animals study turns attention to mismatch repair biology in canine primary pulmonary carcinoma, asking whether the DNA repair proteins MSH2 and MSH6 can be detected by immunohistochemistry and whether their expression correlates with pathologic features. That’s a notable step for a tumor type where veterinary literature has focused more heavily on histology and selected oncogenic drivers, such as HER2, than on mismatch repair markers. (pubmed.ncbi.nlm.nih.gov)
The backdrop is a broader shift in veterinary oncology toward precision diagnostics, even as the evidence base remains uneven across tumor types. Canine pulmonary carcinomas are uncommon, and prior work has centered on diagnostic markers such as TTF-1, napsin A, surfactant protein A, and cytokeratins, along with molecular findings including recurrent HER2 mutations in pulmonary adenocarcinoma. Those studies helped establish how these tumors are classified and how they may parallel subsets of human lung cancer, but they left mismatch repair status largely unexplored. (pubmed.ncbi.nlm.nih.gov)
According to the study abstract provided by the journal listing, the authors examined 17 canine primary pulmonary carcinomas using immunohistochemistry for MCK, TTF-1, MSH2, and MSH6, then assessed relationships with clinicopathologic parameters. The cohort had a median age of 10.6 years. Histologically, 16 tumors were classified as adenocarcinoma and one as adenosquamous carcinoma, with papillary architecture predominating. That profile fits the broader literature, where papillary and acinar patterns are commonly described in canine pulmonary epithelial tumors and where TTF-1 remains an established marker for pulmonary origin, albeit with known overlap with thyroid tumors. (pubmed.ncbi.nlm.nih.gov)
What makes the paper more than a narrow pathology exercise is the timing. Comparative oncology researchers have recently argued that validated canine mismatch repair testing is needed if the field wants to support biomarker-driven trials, especially around immunotherapy. A 2026 study in Molecular Cancer Therapeutics reported development of a canine mismatch repair assay framework and found that mismatch repair deficiency patterns in dogs do not map perfectly onto human assumptions, including species-specific biology involving PMS1. Separate work has also suggested that microsatellite instability may be present across several canine tumor types, including pulmonary carcinomas, although pulmonary sample sizes have been small. (pubmed.ncbi.nlm.nih.gov)
I didn’t find substantial outside expert commentary specifically on this paper, which likely reflects its niche, pathology-focused scope. But the surrounding industry and academic conversation is clear: veterinary oncology is moving toward more individualized cancer characterization, while experts continue to caution that new biomarkers need analytical validation and clinical utility before they’re folded into routine decision-making. That caution is especially relevant here, because a 17-case series can identify patterns, but it can’t establish practice-ready prognostic thresholds on its own. (aaha.org)
Why it matters: For practicing veterinarians, oncologists, and pathologists, the practical takeaway is not that MSH2 or MSH6 testing should immediately be added to every canine lung cancer workup. It’s that the diagnostic vocabulary around these tumors is expanding. If mismatch repair markers eventually prove to correlate with behavior, survival, or treatment sensitivity, they could help refine prognostication or identify dogs suitable for future targeted or immunotherapy-based studies. That possibility is especially relevant in canine pulmonary carcinoma, where other molecular subsets, including HER2-mutant disease, are already being described and linked to biologic differences. (pubmed.ncbi.nlm.nih.gov)
There’s also a systems-level implication for veterinary pathology. As more papers propose molecular or immunohistochemical biomarkers, consistency in tumor classification, staining interpretation, and reporting becomes more important. International veterinary tumor pathology groups have called for harmonized standards precisely because biomarker studies become hard to compare when case definitions and pathology workflows vary. This study, even if preliminary, adds one more reason for clinics, diagnostic labs, and referral centers to watch how canine lung tumors are being phenotyped. (journals.sagepub.com)
What to watch: The next meaningful milestone will be replication in larger cohorts with survival data, treatment data, and ideally paired genomic or microsatellite instability testing, so the field can determine whether MSH2/MSH6 expression is simply descriptive or genuinely clinically actionable in canine lung cancer. (pubmed.ncbi.nlm.nih.gov)